Drug intelligence / Profile preview

IB-003F

Development stage: Unknown
Lead developer: ILiAD Biotechnologies
Modality: Vaccines & Immunotherapeutics

Overview

IB-003F is a drug candidate in the pipeline of ILiAD Biotechnologies LLC, a clinical-stage biotechnology company dedicated to the prevention and treatment of human diseases caused by Bordetella pertussis and other infectious diseases. While the company's primary focus is on its lead pertussis vaccine candidate, BPZE1, IB-003F is listed as one of their drug candidates. Specific details regarding its mechanism of action, primary indication, and development phase are not publicly available in the provided information.

Beyond the preview

Go deeper on IB-003F.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IB-003F.

Explore the full profile